Literature DB >> 21542025

SCOPA-cognition cutoff value for detection of Parkinson's disease dementia.

Dagmar Verbaan1, Martine Jeukens-Visser, Teus Van Laar, Stephanie M van Rooden, Erik W Van Zwet, Johan Marinus, Jacobus J van Hilten.   

Abstract

The SCOPA-Cognition is a reliable and valid test to evaluate cognitive functioning in Parkinson's disease and is widely used in clinical and research settings. Recently, the Movement Disorder Society introduced criteria for Parkinson's disease dementia. The objective of the present study was to use these criteria to determine SCOPA-Cognition cutoffs for maximum accuracy, screening, and diagnosing of Parkinson's disease dementia. A total of 282 patients with Parkinson's disease were assessed with the SCOPA-Cognition and the Movement Disorder Society's Parkinson's disease dementia criteria. From the 275 patients with a complete assessment of the dementia criteria, 12% (n = 32) fulfilled the criteria. Data from 268 patients with complete assessments of both the dementia criteria and the SCOPA-Cognition were used to determine cutoffs for maximum accuracy, screening, and diagnosing of Parkinson's disease dementia. The area under the curve was 0.91 (95% confidence interval, 0.85-0.97), showing a strong association between the dementia criteria and the SCOPA-Cognition. The cutoff for maximum accuracy was 22/23, based on the highest sum of sensitivity (0.80) and specificity (0.87), with positive and negative predictive values of 0.43 and 0.97, respectively. The optimal screening cutoff was 24/25, and the optimal diagnostic cutoff was 17/18. Using the recently published Parkinson's disease dementia criteria as a reference, the current study presents SCOPA-Cognition cutoffs for maximum accuracy, screening, and diagnosing of Parkinson's disease dementia. The availability of SCOPA-Cognition cutoffs for Parkinson's disease dementia may contribute to the scale's usefulness and promote its further use in both clinical and research settings.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21542025     DOI: 10.1002/mds.23750

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; M Veglia; F Piamarta; F Grassi; I M Appollonio
Journal:  Funct Neurol       Date:  2013 Apr-May

2.  Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Authors:  Anne-Marie A Wills; Jordan J Elm; Rong Ye; Kelvin L Chou; Sotirios A Parashos; Robert A Hauser; Ivan Bodis-Wollner; Vanessa K Hinson; Chadwick W Christine; Jay S Schneider
Journal:  Parkinsonism Relat Disord       Date:  2016-10-08       Impact factor: 4.891

3.  Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease.

Authors:  Kristina J Pfeifer; Justus A Kromer; Alexander J Cook; Traci Hornbeck; Erika A Lim; Bruce J P Mortimer; Adam S Fogarty; Summer S Han; Rohit Dhall; Casey H Halpern; Peter A Tass
Journal:  Front Physiol       Date:  2021-04-06       Impact factor: 4.566

4.  Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests.

Authors:  Angela Federico; Alice Maier; Greta Vianello; Daniela Mapelli; Michela Trentin; Giampietro Zanette; Alessandro Picelli; Marialuisa Gandolfi; Stefano Tamburin
Journal:  Parkinsons Dis       Date:  2015-11-08

5.  Patients with dementia syndrome in public and private services in southern Brazil.

Authors:  Carlos Henrique Ferreira Camargo; Giuliano Retzlaff; Filipe Fernandes Justus; Marcelo Resende
Journal:  Dement Neuropsychol       Date:  2015 Jan-Mar

6.  Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease.

Authors:  Carlos Henrique Ferreira Camargo; Eduardo de Souza Tolentino; Augusto Bronzini; Marcelo de Araújo Ladeira; Ronilson Lima; Gustavo Leopold Schultz-Pereira; Marcelo Rezende Young-Blood
Journal:  Dement Neuropsychol       Date:  2016 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.